NICOTINE RECEPTORS
March 1st, 2005
BY MONICA DOBIEPFIZER researchers in Connecticut claim to have developed a new smoking cessation drug that suppresses the desire to smoke rather than weaning a person off the habit by feeding them nicotine. Its scientists discovered a brain receptor that nicotine binds to, designing a drug - Varenicline - that also clings to these neural cells, cancelling and preventing nicotine cravings. It is currently in phase three testing in the United States, normally the last one before gaining Food and Drug Administration (FDA) approval. The last drug claiming to have ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.